Shake-Up Underway at Susan G. Komen Foundation

It’s been a rough year for the Susan G. Komen Foundation. Months after weathering the backlash brought on by their decision to eliminate funding of Planned Parenthood chapters to help provide breast exams, the group appears ready to start over with some new faces in charge.

Via KING5 News:

The Susan G. Komen for the Cure shook up its top leadership Wednesday by announcing the resignation of its president and shifting role for its CEO and founder. Two members of its Board of Directors also announced their resignations.

Komen President Liz Thompson announced plans to leave the organization in September. Meanwhile, Komen Founder and CEO Nancy Brinker will shift to a new management role as chair of the Komen Board Executive Commiittee when the search for a new senior executive is finished.

Komen also announced, Brenda Lauderback and Linda Law, who have served on their board since 2008 and 2009 respectively, are leaving the board of directors.

The shift comes as little surprise, other than the fact that it took so long. The attempt to stop its funding of Planned Parenthood became the type of public relations nightmare that non-profits dread, and despite eventually backing down, it was clear that the organization took a huge hit for its mistake.

Komen claims the change in leadership is not related to the Planned Parenthood incident.

Like this story? Your $10 tax-deductible contribution helps support our research, reporting, and analysis.

For more information or to schedule an interview with contact

Follow Robin Marty on twitter: @robinmarty

  • cindy-sullivan

    Nancy’s Twitter states that she promised her sister to put an end to breast cancer and she raised millions upon millions of dollars to do it. Yet the Komen foundation refused funding for the world’s first preventive breast cancer vaccine that could do just that; put an end to breast cancer!


    The Pink Vaccine was developed by Dr. Vincent Tuohy of the Cleveland Clinic and is 100% effective in preventing breast cancer in mice. Further, it reduced tumor size in mice that already had breast cancer. It’s our biggest hope yet and it’s sitting on a shelf at the Cleveland Clinic awaiting a mere $6 Million in funding to get it to clinical trials in humans.


    One in 8 women will be diagnosed with breast cancer in her lifetime yet Komen refused funding three times for our best hope at preventing it. My tax deductible contributions are going directly to the Cleveland Clinic.

    Prevention is the Cure!


    More Here: